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Vaccine development toolVaccination remains the most successful and effective mechanism of pathogen control. However, their
development and deployment in epidemic settings have been limited, and the 2015 Ebola outbreak in
West Africa identified several bottlenecks linked to a lack of investment in pathogen research, infrastruc-
ture or regulation. Shortly after this outbreak, the UK Government established the UK Vaccine Network to
ensure the UK is better prepared to respond to pathogens outbreaks of epidemic potential. As part of their
work, the network commissioned the creation of a Vaccine Development Tool (http://www.vaccinedevel-
opment.org.uk/) to serve as a guide to the key stages in vaccine development. The tool also set out to cap-
ture the key, rate-limiting bottlenecks in the development of vaccines against emerging infectious
disease such that corrective action could be taken, be it through research, funding, infrastructure and pol-
icy, both in the UK and internationally. The main research bottlenecks were related to understanding
pathogen biology, identification of appropriate animal models and investment in the manufacturing
sciences, especially into process development. Infrastructure gaps in GMP manufacturing and fill-finish
were also identified and limitations in GMO regulation and regulatory and ethical approvals, especially
for outbreak pathogens required new policy initiatives. The UK Vaccine Network has since begun work
to correct for these limitations with a series of funding calls and development programmes. This paper
seeks to summarise the Vaccine Development Tool and its key findings.
 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Timely response to epidemics requires the development, manu-
facture and distribution of vaccine. Activities by the UK Vaccine
Network (UKVN) and the WHO have seen the identification of sev-
eral pathogens that have epidemic potential [1]. However, the
development of effective vaccines against these pathogens requires
improved coordination between policy makers, funders, research-
ers, vaccine manufacturers, and regulators, if we are to develop
and deploy vaccines to mitigate the spread of epi- or pandemics
[2].
Set in the context of the Ebola outbreak that began in 2014,
multiple stakeholders were mobilised to respond to the humani-
tarian crisis of this escalating outbreak. Although there was no
licenced Ebola vaccine available, approximately fifteen different
vaccines were in preclinical development, including DNA vaccines,virus-like particles and viral vector [3]. Levine et al. [4] described
how these candidates had largely been developed as part of the
bioterrorism preparedness programme, BioShield, in the United
States. Due to the relatively low geographic prevalence of infection
there was a limited market and thus a poor case for industry to
develop a vaccine for commercial purposes. However, concerns
over the potential use of Ebolavirus as a bioterrorism agent
resulted in a number of stockpiled sources that had undergone
testing in animal models [4].
As the Ebola epidemicworsened, the availability of small vaccine
stockpiles, taken together with the threat of further spread, catal-
ysed stakeholder engagement to test the vaccine in humans to
determine safety for potential deployment. Researchers, industrial-
ists, regulators, and fundersworked together to expedite the process
of carrying out first-in-man trials of the Ebola vaccine1. Severalborative
st 2014
sortium-
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although this outbreak also served to highlight the necessity of effec-
tive public health systems and infrastructure, and community
engagement in order to mitigate disease spread through cultural or
social practices [6]. In the case of Ebola, it was fortuitous that several
candidate vaccines were already in development and immense global
efforts made the vaccine available. However, this also conspicuously
highlighted that nations around the world need to be better prepared
for outbreaks of all infectious diseases, particularly those with the
potential for high levels of morbidity and mortality, and that other
measures to control infection spread should also be implemented [7].
The United Kingdom (UK) has a strong international reputation
for scientific research and innovation, and a long history in vacci-
nology. Along with other countries, the UK Government mobilised
resources to manage the Ebola outbreak, as well as played a role in
testing Ebola vaccines in the UK, and West Africa. Alongside these
efforts, the UK Chief Medical Officer for the Department of Health
and Social Care (DHSC), Dame Sally Davies, raised the question to
government and related stakeholders – what could the UK do to
be better prepared for future outbreaks of infectious diseases? A part-
nership was instigated across the DHSC, the UK Medical Research
Council (MRC) and the Biotechnology and Biological Sciences
Research Council (BBSRC), who then worked together to establish
a ‘UK Vaccine Network’ (UKVN, www.gov.uk/government/groups/
uk-vaccines-network) bringing together a small number of special-
ists from industry, academia and relevant funding bodies to make
targeted investments in specific vaccines and vaccine technology
for infectious diseases with the potential to cause an epidemic.
At its inaugural meeting in July 2014 the UKVN discussed
potential priority areas for investment. Members agreed that four
Working Groups (WGs) with the following foci:
WG1: To prioritise 10–12 pathogens most likely to cause an
epidemic or pandemic in the short to medium term.
WG2: To rationalise where and when vaccine development
resources should be prioritised when intervention is possible.
WG3: To understand the challenges in vaccine development
and the key rate limiting steps for any given vaccine in
development.
WG4: To address manufacturing capacity for vaccines.
This paper describes the activities undertaken by Working
Group 3 on Vaccine Development. The group created a visual pro-
cess mapping tool to better understand the potentially rate-
limiting bottlenecks associated in moving a vaccine candidate from
discovery through to development and early Phase clinical trials;
then into clinical manufacture and Phase 3 trials. The primary pur-
pose of the tool was to act as a visual aid for early discovery and
development scientists, highlighting the major steps required to
fully develop any experimental vaccine. The secondary, and crucial
purpose of the tool, was to identify any generic bottlenecks that
may slow down development. Identifying such strategic limita-
tions may identify corrective actions, that may in turn help to over-
come potential delays or setbacks when expediting vaccine
development during epidemics. Actions could be taken by policy
makers to correct for limitations in regulation, funders to identify
limits in scientific knowledge that could be corrected with appro-
priate investment, and for government and trans-national organi-
sations to consider local and global response. Though the genesis
of this tool was considered in the context of epidemic prepared-
ness, the tool itself is sufficiently far-reaching that it can be utilized
by the wider vaccine community. Considering the global nature of
vaccines, it is important to understand the interdependencies that
exist between discovery, development and manufacture. This tool
gives scientists vision of the considerations that will need to be
made along the development process. In taking a much more holis-
tic approach to vaccine development it is hoped that this can sup-port other international such as the Global Vaccine Action Plan [8],
which relies on the continued supply of vaccines to meet immu-
nization targets. Thus, the tool serves multiple users and purposes,
and we report on its main findings in this paper.2. Methods
2.1. Mapping the processes
After initial literature consultations, a basic schematic overview
of the major steps was created, which then fell into four main
areas: (i) pre-clinical discovery; (ii) pre-clinical development; (iii)
manufacturing; and (iv) clinical trials. Several subgroups were con-
vened to discuss these areas; membership was drawn from the
UKVN, a core group of specialists that made up WG3 and further
expertise consulted according to need. Process schematics were
made, and members undertook interactive discussions to add in,
remove, and reorganise steps. The UKVN Secretariat led on organ-
ising a series of iterative workshops that repeated this process sev-
eral times; each time a skills gap analysis was carried out to ensure
appropriate expertise was representing different disease/vaccine
interests, and from across the vaccine sector from academic and
industry discovery, development, regulation, manufacturing and
clinical trials. The repeated process of interactive mapping, refine-
ment of core documents, and presentation of progress back to the
subgroups stimulated dialogue on the map as a whole. This was a
concerted effort to break down silos between disciplines and sec-
tors, and address how choices made in early discovery may affect
the later development pathway.2.2. Making the tool
Once the iterative, interactive working subgroups had met to
agree the final nodes and bottlenecks on the map, the final figures
were transcribed into PowerPoint. These images were then used as
the basis for interactive webpages, which were constructed by the
MRC Regulatory Support Centre (MRC RSC, https://mrc.ukri.org/re-
search/facilities-and-resources-for-researchers/regulatory-sup-
port-centre/). The MRC RSC offered designs for the main menu,
layout and colour scheme and once agreed with the Secretariat,
all graphics for the tool were drawn using Adobe Illustrator then
saved in a web-friendly format. The website was built in Dream-
weaver using HTML5 coding. Efforts were made to make the site
responsive to different devices, and while this was possible for
the text it was not possible to do so for the maps due to the
complexity of the subject. The final version can be seen at
www.vaccinedevelopment.org.uk.3. Results
The process mapping workshops culminated in production of a
website, with standalone pages for maps that distinguished the fol-
lowing major subdivisions: (1) Target Product Profile (TPP); (2)
Pre-clinical Discovery; (3) Pre-clinical Development; (4) Clinical
Development; and (5) Regulatory Affairs and Ethical Approvals
(Fig. 1). Due to the mandate and remit of the tool to be used by
the UKVN for the development of vaccines for outbreaks, WG3
agreed that the tool did not need to address steps for market access
and authorisation, as outbreak vaccines would not normally
undergo this process – instead being deployed in small populations
according to need once necessary evidence on safety and immuno-
genicity had been achieved.
Table 1
Summary of the vaccine development tool bottlenecks. These bottlenecks identify
generic rate-limiting stages in vaccine development that could be alleviated through
further research spending, changes in policy of investment into infrastructure.
Stage in development Short description Type of bottleneck
Pre-clinical discovery  Pathogen biology including
- Human-host immunology
- Pathogen Challenge model
 Freedom to operate
 Research
 Policy
Pre-clinical development  Process development
including,
- Critical process parameters
- Critical quality attributes
- Adjuvants and formulation
 Animal model choice
 Scale-up and clinical
manufacture
- GMP bulk
- GMP fill-finish
 Research
 Research
 Infrastructure
Clinical development  GMO regulation
 Trial sites and NRA approval
 Regulatory and ethical
approval
 Policy
Fig. 1. Overview of the tool with Target Product Profile as the entry point. Giving
consideration into what is actually required by the target population is best
captured by the target product profile and should be used as a reference document
during the development process.
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The Target Product Profile (TPP) is a descriptive document that
sets out clear parameters for the characteristics of the desired end
product, its intended use, and market. It is the designated entry
point into the process map. This came about through repetitive
discussions that prevailed on the importance of the TPP at all
stages in development; in simple terms, to know what it is you
are making, and for whom. WG3 agreed that the significance of
the TPP and the relevance to even the earliest exploratory basic
science work, should not be underestimated, therefore promi-
nently placing the TPP, aimed to engage early discovery scientists
to consider what the end product is, and how the choices made
during pre-clinical discovery and development influence them.
The consensus opinion within the working group was that the
TPP should be seen as a strategic planning document that should
be utilised as a benchmark as data emerges. During normal devel-
opment, this is a tool for novel vaccine creation. However, in an
outbreak situation, the TPP acts as an essential checklist under
accelerated timescales. It is worth noting that that the importance
of TPPs is widely shared and recent work by the WHO and CEPI
includes creating standard TPPs for priority pathogens.
3.2. Bottlenecks
Iterative workshops hosted ongoing discussion on what was
involved in each step, and where might rate limiting steps slow
down development. There was agreement that almost anything
could be described as a bottleneck in that each step is necessary,
and by the nature of discovery research and development, such
endeavours take time. However, in order to scrutinize the bottle-
necks that could potentially be ameliorated by corrective action
or investments by governments, research funders and policy mak-
ers, WG3 agreed that the tool should only identify steps where cor-
rective action could be taken that could potentially accelerate
vaccine development. The main bottlenecks and the corrective
action required are summarised in Table 1. An additional impor-
tant consideration, was that the identification of these bottleneck
‘nodes’ should be sufficiently generic so as to be applied to a range
of vaccine types, and pathogens – thus WG3 refined the key steps
to common denominators that were shared across approaches.
Overall, many of the bottlenecks focused around gaps in funding
for scientific knowledge, training, and infrastructure. An additional
item was harmonisation of regulation, especially with regards to
the release of genetically modified organisms (GMOs). The bottle-
necks can readily be seen on the process map by clicking ‘show
bottlenecks’ on each map page; belowwe describe the main bottle-
necks highlighted at each stage.
3.2.1. Pre-clinical discovery
Within pre-clinical discovery, understanding pathogen biology
and developing the appropriate animal challenge models are seenas significant limiting factors, especially with emerging infectious
disease. The ability to screen, test, and verify potential new anti-
gens is of critical importance. Increased research funding into stan-
dardised methodologies for in vitro and in vivo testing and work
into human-livestock host immunology would be critical to
increase capacity.
As lead candidates are identified, ensuring that the work has the
appropriate freedom to operate becomes increasingly important. A
review of the Intellectual Property landscape including searches on
the antigen, cell line, and biological methods employed to create
them are required and time to completion could be as little as
three months, but increases with complexity. Conducting a free-
dom to operate review is an important step towards commerciali-
sation. Yet, in an outbreak scenario, special regulations such as
compulsory licensure and step-in rights may allow this issue to
be side-stepped, but would require further clarification in policy.
3.2.2. Pre-clinical development
Pre-clinical development is a complex, multi-step, and time-
consuming process (Fig. 2). It requires that vaccine candidates
undergo strain development and confirmation of antigen presenta-
tion, verified by animal studies. This is followed by process devel-
opment to ensure that a scalable, robust, and GMP compliant
manufacturing process is created. Material generated at the end
of pre-clinical development can be used for animal toxicology
studies and forms the basis of a clinical trial application.
The first bottleneck encountered is in strain development. Some
development work can occur using a research cell bank, however
research cell banks are generally not to GMP standards therefore
delays at later stages can be avoided by ensuring banks are GMP
compliant. This will often require re-cloning into traceable cell
lines that are GMP certified and free of any adventitious agent.
Major bottlenecks are around Process Development to create a
scalable, GMP compliant, manufacturing process and the determi-
nation of the critical process parameters. At this stage manufactur-
ers must address if the vaccine can in fact be manufactured in a
scalable process. There is no generic manufacturing process for
vaccines, thus almost all processes are designed from the bottom
up, which adds costs and delays to any future intervention plan.
Platform manufacturing technologies are a method to overcome
this issue by streamlining manufacturing with generic operations
into which your selected antigen(s) can be introduced. Viral vec-
tors are one such platform technology that was effectively
Fig. 2. Pre-clinical simplified development map. This map summarises the main bottlenecks in pre-clinical development following lead candidate identification. The target
product profile is re-evaluated during this process to ensure it correctly reflects manufacturing data, and developers are encouraged to liaise with regulatory bodies and
ensure early input at any relevant stage.
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recombinant sub-unit vaccine technologies are another platform
technology that could be used in other epidemics and has been
successfully demonstrated in context of influenza vaccines [11].
Other advances in nucleic acid based vaccines, such as DNA and
RNA, offer a future, though as yet unrealised potential, for generic
manufacturing and release testing of vaccines. The determination
of the range of physical, chemical, biological, or microbiological
properties that ensure the quality of the desired product, is
described as ‘Critical Quality Attributes’ (CQA) and requires well-
defined analytics which in the long term can reduce Quality Con-
trol (QC) costs. Finding suitable analytics that can resolve complex
antigen structure, increase understanding of degradation pathways
and formulation needs is a continuing bottleneck. Funders must
ensure that process development, manufacturing, and analytics
are not overlooked in future research calls.
Further bottlenecks are encountered during animal in vivo stud-
ies; characterising immunogenicity and reactogenecity in relevant
animal models is imperative for taking forward vaccine candidates
into Phase 1. With this model there are further potential bottle-
necks associated with Home Office approvals, and Containment
Level 3 and 4 facilities depending on the pathogen of study, and
supply of animals.
GMP manufacturing is an infrastructure bottleneck that
requires funders and policy makers to examine the pressures upon
the current manufacturing model. Almost all vaccine manufactur-
ers operate at capacity and are dedicated to production of a single
product. ‘Step-in’ rights in an emergency scenario will disrupt sup-
ply of an essential vaccine, but also cause delay. Recruiting a CMO
to the task may help to alleviate the situation, but essential train-
ing and know-how is required. Furthermore, some sites may only
be suitable for certain vaccines classes, which can range from pro-
tein sub-unit vaccines to live viral and bacterial vaccines. Based on
vaccine class, facilities may not have the appropriate containment
level for bulk manufacture of the drug substance, or the fill-finish
for drug product. Indeed, many facilities do not have fill-finish
operations co-located and fill-finish is also a bottleneck in clinical
development due to the limited number of appropriate sites and
the volume of vials required for Phase 2 and 3 trials.
The UK Government, with the UKVN providing evidence and
advice, has identified manufacturing infrastructure as a significant
bottleneck, and it has sought to invest into a new VaccineDevelopment and Manufacturing Centre (https://www.gov.
uk/government/news/medicine-and-vaccine-manufacturing-cen-
tres-apply-for-funding). Other organisations, such as CEPI [12],
have also issued calls for proposals into new platform manufactur-
ing technologies (cepi.net). The situation exists under the status
quo that we may have a vaccine that can be utilised to fight a
future epidemic, but not have the manufacturing capacity to
enable production and distribution. These latest calls seek to
reverse current limitations.3.2.3. Clinical development
Many of the priority pathogens are prone to sporadic outbreaks,
and due to potential lethality, it will not be possible to conduct full
Phase 3 trials, and even Phase 2 studies may prove challenging in a
human population due to the unpredictable nature of these out-
breaks. Nonetheless, the sequential clinical trial steps that would
comprise the ‘normal’ steps in development of a vaccine being
taken forward for licensure have been incorporated into the tool.
Clinical trials require great investment and resource to execute,
and the lengthy nature of the process could itself be described as
a bottleneck; for the purposes of the tool however, we highlight
fives steps within clinical development. Current GMO regulations
do not distinguish vaccines based on viral vectors, or live, replica-
tion incompetent vectors based on bacteria and viruses. Current
regulation stipulates that use of GMO vaccines is done so under
‘contained use’ or ‘deliberate release’ protocols to prevent release
into the environment. Consequently, this may involve obtaining
separate approvals, modifications to the trial site, modified proce-
dures for sterilising, administering and disposing, separate storage
facilities and special training of staff to handle GMOs. Overall, this
whole area would benefit a revision of regulations and derogating
the use of common vaccine vectors in separate regulations from
the currently applicable GMO guidance would have a substantial
beneficial impact in speeding up approvals.
Obtaining Regulatory Approval may be especially difficult in the
context of an international trial, where local rules may differ from
country to country, or the National Regulatory Authority (NRA)
itself may have insufficient experience and seek expert opinions,
which can further delay the process. Engagement with the NRA
at an early stage is essential, as seeking opinion on the proposed
trial design can capture any ‘in country’ requirements. The
2 http://www.vaccinedevelopment.org.uk/outreak-casestudies.html.
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sites are not approved to work with GMO vaccines, or there are
other limitations such as lack of infrastructure, skilled personnel,
and capacity. Working with credible and experienced partners will
help to minimise delay and several clinical trial networks already
exists to facilitate clinical development, some of which are patho-
gen specific that can further minimise this bottleneck.
To overcome these bottlenecks, finding clinical trial sites and
experienced NRAs that can act as credible authorities is essential,
and early discussions need to occur in tandem to development
and production to avoid delays.
3.2.4. Regulatory affairs
The process mapping tool emphasises the importance of ethical
and regulatory considerations throughout the entire process, as the
iterative workshops continually highlighted the importance of
early engagement so the appropriate advice and input shape the
R&D. The tool provides an overview and signposting to other organ-
isations and information sources, as many outbreak vaccines may
never go through market authorisation due to there being no com-
mercial incentive for the manufacturers. Nevertheless, there will be
several stageswhere necessary approvalsmust be obtained in order
to proceed with developing and testing a candidate. For regular
marketing authorization in the EU, vaccine developers must pro-
vide a full development dataset of pre-clinical and clinical trial
results to evidence Clinical Safety and Efficacy, as well as evaluation
of a positive benefit-risk ratio. The mapping tool highlights that:
 To discuss the TPP the UK Medicines and Healthcare products
Regulatory Agency (MHRA) can be approached at any time.
 Animal work is regulated under the Animals (Scientific Proce-
dures) Act 1986 (ASPA). A UK Government Home Office licen-
sure must be provided at an institutional, personal and project
level.
 The use of GMO vaccines is regulated by separate legislation,
and approval must be given by the Health and Safety Executive
(HSE).
 To carry out experimental medicine studies of immune
responses in humans the Health Research Authority (HRA) pro-
vides ethical approvals through the Research Ethics Service
(RES) for projects in the NHS (led from England).
 Clinical Trial Authorisation (CTA) is made through a formal
application to the MHRA. Trialists must provide information
on the mode of action, nature of the target, animal model stud-
ies and an IMP dossier with preclinical toxicology data, and any
human mechanistic/proof of concept studies.
Though these regulations are specific for the UK, many other
countries require a similar level of scrutiny.
In the case of life-threatening infections, it is conceivable that
many of the priority vaccines under development will ultimately
never undergo the standard clinical trials process and be used in
an outbreak situation under EUAL [13]. In these circumstances, it
is imperative to test novel vaccine candidates in well characterised
animal models. Previously applied to defence vaccines due to the
limitations of clinical testing, the FDA Animal rule [14] may provide
a pathway to test novel vaccine candidates. In outbreak settings, as
was the casewithEbola, it is possible to undertake anemergencyuse
protocol and expedite authorisation to ensure a promising vaccine
candidate can be deployed for human use, if it is justified as major
interest for public health and/or therapeutic innovation.
3.3. Case studies
Once a generic framework that could be applied to vaccine R&D
broadly was established, the working group undertook a series ofmeetings applying the process map to three case studies of differ-
ent vaccine candidates under development for three of the UKVN’s
priority pathogens: MERS Viral Vector vaccine, Zika protein sub-
unit/VLP vaccine (Fig. 3), and the Prokarium Vaxonella Plague
vaccine (Fig. 4). The case studies can be accessed through the main
landing page of the process map2.
MERS was selected as there are several candidates in later
stages of development, including the viral vectored vaccine candi-
date ChAdOx1 MERS. The viral vector approach overcomes a num-
ber of bottlenecks to speed up development, mainly impacting on
the preclinical development stages to overcome delays that would
be associated with masterseed bank production, pre-formulation
work/in vitro and in vivo, and lead identification. Antigen identifi-
cation bottlenecks are also overcome, through straightforward
selection of the spike protein (the major external antigen of coro-
naviruses) which elicits neutralising antibodies to the receptor
binding domain [15]. The bottlenecks that remains relevant from
the generic tool are: basic understanding of human/livestock host
immunology; using an appropriate animal challenge model
(camels would be suitable, but few places have facilities for such
a large model); and the three main bottlenecks in clinical develop-
ment of obtaining ethical and regulatory approval, working with
vaccines classified as GMOs, as the viral vector platform has been
altered genetically from its original form, and the availability of
overseas trial sites.
More bottlenecks were identified when applying the Vaccine
Development Process Map to a novel Zika vaccine. At the time of
the UKVN formation, Zika was little heard of, and had only modest
investment as a potential emerging virus in UK research funding
portfolios. As the work of the UKVN progressed, the Zika outbreak
unfolded, and funders in the UK and internationally were mobi-
lised to increase investments. The UKVN immediately added Zika
to the priority pathogen list, and contributed to a number of fund-
ing streams to support vaccine R&D. Applying the process mapping
tool to such an emerging pathogen, allowed the visualisation of the
significant number of unknowns and challenges when dealing with
a little-known emerging disease without platform approaches
(Fig. 3). In the earliest pre-clinical discovery stage, pathogen biol-
ogy and host immunology were both rate limiting, particularly in
identifying regions of the virus that could be used as a possible
antigen. In vitro studies and deploying an in vivo challenge model
were also rate limiting as the generation of reagents and the appro-
priate assays need to be established. Without a robust set of assays
and generation of some antigen in the early discovery phase, the
bottleneck would be overcome however identification of the surro-
gate/correlate of protection in the appropriate challenge models
will be important. It should be noted that many vaccines have
launched without the establishment of correlates of protection
and will depend on the licensure sought and the severity of the dis-
ease and its outbreak.
In pre-clinical development, due to the novelty of the vaccine,
process development, assays, adjuvantisation and formulations
were identified as bottlenecks. Time could be saved if a platform
technology was used for this vaccine, circumventing many steps
in process development and formulation. In clinical development,
deploying a human challenge model to study the response to a vac-
cine studies were considered rate-limiting, and it must be noted
that in the case of emergency or experimental licensure, a strategy
might be to establish some animal challenge data and seek to
establish safety data in a Phase 1 trial before expansion into a
Phase 2a/b trial. However, demonstrating efficacy can only be
one in endemic or outbreak situations and will require early
Fig. 3. Zika case study summary. As a relatively neglected pathogen until recently,
much of the bottlenecks identified are in the pre-clinical discovery phase, which
requires antigen identification and development of assays and challenge models.
The need for a new vaccine also incurs bottlenecks in the pre-clinical development
phase and in clinical development.
Fig. 4. Plague case study summary. The total number of bottlenecks is reduced due
to the use of a live bacterial vector system being exploited as a platform technology.
Plague antigens are already known and well characterised, thus, many of the
bottlenecks shift to clinical development and testing of the vaccine candidate.
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has the potential to be rate-limiting.
A plague vaccine potentially has dual application: the develop-
ment path could be in collaboration with government agencies in
producing an anti-bioterror vaccine but could be expanded and
developed as a vaccine against endemic disease in regions such as
Madagascar. This dual nature affects the way we think about the
TPP and development path. As with theMERS case study the Plague
Vaccine exploited a platform technology – Prokarium’s Vaxonella
platform – thus many bottlenecks, particularly in preclinical devel-
opment,were circumvented (Fig. 4). Themain bottlenecks are in the
clinical phase and animal rule regulations necessary to follow for
licensure and are particular to this pathogen and vaccine approach,
and included: Quality control; Phase II regulatory requirements fortwo animal models; Fill Finish; and in Phase II safety studies, meet-
ing requirements for licensure regulations.
The case studies have demonstrated how useful the process
map can be in vaccine development, and how using platform tech-
nologies enables many development steps to be circumvented and
thus overcome rate-limiting steps, which could be vital in an out-
break situation where speed of development must be minimised
where possible.
3.4. Prioritisation guide
As an additional feature, the tool also presents some of the work
completed by WG2, which was undertaken to better understand
the feasibility and challenges of developing vaccines for the major
UKVN prioritised pathogens. The UKVN members agreed that to
develop a new vaccine might not always be the most appropriate
response in an outbreak setting, particularly if a candidate vaccine
is early stage and presents significant R&D or manufacturing chal-
lenges. Thus, it may be more appropriate to deploy other health-
care interventions to manage the disease, such a therapeutic
antibodies or containment procedures.
The prioritisation guide addresses the ‘Technical Feasibility’ of
creating a vaccine together with ‘Public Health Value’ based on
pathogen severity and alternatives to vaccination. A final consider-
ation was the time scale and cost of development, with the single
criterion to address the available vaccine candidate(s), considering
the stage in development of any existing candidates. This included
manufacturing considerations, and whether any vaccine may
already be stockpiled.
Each criteria has a red, amber or green status, and taken
together will enable decision-making on the suitability of pursuing
vaccine R&D in an outbreak setting.
4. Conclusion
This tool represents a first step towards understanding the lim-
iting factors in vaccine development and epidemic preparedness.
However, there are still several key outstanding challenges it does
not fully capture. The first is sustained funding for this problem,
which is partly address through the creation of the Coalition for
Epidemic Preparedness Innovation (CEPI, www.cepi.net), however
improved co-ordination is still required between industry, acade-
mia, government and international organizations, such as the
WHO. This will be a key priority for policy makers in the future.
Infrastructure and manufacturing capacity needs to be accurately
assessed, especially fill-finish capacity for the different vaccine
types/classes. Additionally, continued research is required to better
understand the correlates of protection, appropriate animal models
and, of course, the discovery of new antigens that can protect
against these emerging pathogens.
An extraordinary array of technologies are under development
that have the potential to change our ability to respond to emerg-
ing infectious diseases. Amongst these, viral vector and subunit
vaccines are at the forefront, however future innovations with
nucleic acid based vaccines are on the horizon. Currently, there
are no DNA or RNA vaccines licensed for human use. Yet should
this milestone be reached, many of the bottlenecks described cur-
rently will be eliminated. In the meantime, funders, governments
and policy makers must all focus to overcome the existing bottle-
necks identified and employ better co-ordination to overcome
future epidemic threats.
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